scientific
按立场 · 1 takes across the edition
Nature Biotechnology · United Kingdom · Intellia files first in-vivo CRISPR therapy with the FDA
Frames Intellia's filing as the field's first in-vivo CRISPR therapy reaching the FDA, contrasting permanent in-body editing of a liver gene against ex-vivo approaches and flagging the regulatory precedent a one-time genome edit sets.
“Intellia heads to FDA with first in vivo CRISPR-based gene editing therapy.”